- •PROGRESS IN BRAIN RESEARCH
- •List of Contributors
- •Preface
- •Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects
- •Introduction
- •Prevalence of glaucoma
- •PAC suspect
- •PACG
- •Incidence of glaucoma
- •Blinding effects of glaucoma
- •Abbreviations
- •Acknowledgment
- •References
- •Predictive models to estimate the risk of glaucoma development and progression
- •Risk assessment in ocular hypertension and glaucoma
- •Risk factors for glaucoma development
- •Intraocular pressure
- •Corneal thickness
- •Cup/disc ratio and pattern standard deviation
- •The need for predictive models
- •Predictive models for glaucoma development
- •Predictive models for glaucoma progression
- •Limitations of predictive models
- •References
- •Intraocular pressure and central corneal thickness
- •Main text
- •References
- •Angle-closure: risk factors, diagnosis and treatment
- •Introduction
- •Mechanism
- •Other causes of angle closure
- •Risk factors
- •Age and gender
- •Ethnicity
- •Ocular biometry
- •Genetics
- •Diagnosis
- •Acute primary angle closure
- •Angle assessment in angle closure
- •Gonioscopy technique
- •Ultrasound biomicroscopy (UBM)
- •Scanning peripheral anterior chamber depth analyzer (SPAC)
- •Management
- •Acute primary angle closure
- •Medical therapy
- •Argon laser peripheral iridoplasty (ALPI)
- •Laser peripheral iridotomy (PI)
- •Lens extraction
- •Monitoring for subsequent IOP rise in eyes with APAC
- •Fellow eye of APAC
- •Chronic primary angle-closure glaucoma (CACG)
- •Laser peripheral iridotomy
- •Laser iridoplasty
- •Medical therapy
- •Trabeculectomy
- •Lens extraction
- •Combined lens extraction and trabeculectomy surgery
- •Goniosynechialysis
- •Summary
- •List of abbreviations
- •References
- •Early diagnosis in glaucoma
- •Introduction
- •History and examination
- •Quantitative tests and the diagnostic process
- •Pretest probability
- •Test validity
- •Diagnostic test performance
- •Posttest probability
- •Combing test results
- •Selective tests of visual function
- •Early glaucoma diagnosis from quantitative test results
- •Progression to make a diagnosis
- •Conclusions
- •Abbreviations
- •References
- •Monitoring glaucoma progression
- •Introduction
- •Monitoring structural damage progression
- •Monitoring functional damage progression
- •Abbreviations
- •References
- •Standard automated perimetry and algorithms for monitoring glaucoma progression
- •Standard automated perimetry
- •Global indices
- •HFA: MD, SF, PSD, CPSD
- •Octopus indices: MD, SF, CLV
- •OCTOPUS seven-in-one report (Fig. 2)
- •SAP VF assessment: full-threshold strategy
- •SAP VF defects assessment: OHTS criteria
- •SAP VF defects assessment: AGIS criteria
- •SAP VF defects assessment: CIGTS
- •Fastpac
- •Swedish interactive threshold algorithm
- •SAP VF assessment: the glaucoma staging system
- •SAP: interocular asymmetries in OHTS
- •SAP, VF progression
- •SAP: the relationship to other functional and structural diagnostic tests in glaucoma
- •SAP, FDP-Matrix
- •SAP, SWAP, HPRP, FDT
- •SAP: the relationship between function and structure
- •SAP, confocal scanning laser ophthalmoscopy, SLP-VCC
- •SAP, optical coherence tomography
- •SAP and functional magnetic resonance imaging
- •References
- •Introduction
- •Retinal ganglion cells: anatomy and function
- •Is glaucoma damage selective for any subgroup of RGCs?
- •Segregation
- •Isolation
- •FDT: rationale and perimetric techniques
- •SWAP: rationale and perimetric techniques
- •FDT: clinical data
- •SWAP: clinical data
- •Clinical data comparing FDT and SWAP
- •Conclusions
- •References
- •Scanning laser polarimetry and confocal scanning laser ophthalmoscopy: technical notes on their use in glaucoma
- •The GDx scanning laser polarimeter
- •Serial analysis
- •Limits
- •The Heidelberg retinal tomograph
- •Limits
- •Conclusions
- •References
- •The role of OCT in glaucoma management
- •Introduction
- •How OCT works
- •How OCT is performed
- •Evaluation of RNFL thickness
- •Evaluation of optic disc
- •OCT in glaucoma management
- •New perspective
- •Abbreviations
- •References
- •Introduction
- •Technology
- •Visual stimulation
- •Reproducibility and habituation of RFonh
- •Retinal neural activity as assessed from the electroretinogram (ERG)
- •The Parvo (P)- and Magno (M)-cellular pathways
- •Physiology
- •Magnitude and time course of RFonh in humans
- •Varying the parameters of the stimulus on RFonh
- •Luminance versus chromatic modulation
- •Frequency
- •Effect of pattern stimulation
- •Neurovascular coupling in humans
- •Clinical application
- •RFonh in OHT and glaucoma patients
- •Discussion
- •FLDF and neurovascular coupling in humans
- •Comments on clinical application of FLDF in glaucoma
- •Conclusions and futures directions
- •Acknowledgements
- •References
- •Advances in neuroimaging of the visual pathways and their use in glaucoma
- •Introduction
- •Conventional MR imaging and the visual pathways
- •Diffusion MR imaging
- •Functional MR imaging
- •Proton MR spectroscopy
- •References
- •Primary open angle glaucoma: an overview on medical therapy
- •Introduction
- •When to treat
- •Whom to treat
- •Genetics
- •Race
- •Ocular and systemic abnormalities
- •Tonometry and pachymetry
- •How to treat
- •Beta-blockers
- •Prostaglandins
- •Alpha-agonists
- •Carbonic anhydrase inhibitors (CAIs)
- •Myotics
- •Fixed combinations
- •References
- •The treatment of normal-tension glaucoma
- •Introduction
- •Epidemiology
- •Clinical features
- •Optic disk
- •Central corneal thickness
- •Disease course
- •Risk factors
- •Intraocular pressure
- •Local vascular factors
- •Immune mechanisms
- •Differential diagnosis
- •Diagnostic evaluation
- •Therapy
- •IOP reduction
- •Systemic medications
- •Neuroprotection
- •Noncompliance
- •Genetics of NTG
- •Abbreviations
- •References
- •The management of exfoliative glaucoma
- •Introduction
- •Epidemiology
- •Ocular and systemic associations
- •Ocular associations
- •Systemic associations
- •Pathogenesis of exfoliation syndrome
- •Mechanisms of glaucoma development
- •Management
- •Medical therapy
- •Laser surgery
- •Operative surgery
- •Future treatment of exfoliation syndrome and exfoliative glaucoma
- •Treatment directed at exfoliation material
- •References
- •Laser therapies for glaucoma: new frontiers
- •Background
- •Laser iridotomy
- •Indications
- •Contraindications
- •Patient preparation
- •Technique
- •Nd:YAG laser iridectomy
- •Argon laser iridectomy
- •Complications
- •LASER trabeculoplasty
- •Treatment technique
- •Mechanism of action
- •Indications for treatment
- •Contraindications to treatment
- •Patient preparation and postoperative follow-up
- •Complications of the treatment
- •Selective laser trabeculoplasty
- •Results
- •LASER iridoplasty
- •Indications
- •Contraindications
- •Treatment technique
- •Complications
- •LASER cyclophotocoagulation
- •Introduction
- •Indications and contraindications
- •Patient preparation
- •Transpupillary cyclophotocoagulation
- •Endoscopic cyclophotocoagulation
- •Transscleral cyclophotocoagulation
- •Transscleral noncontact cyclophotocoagulation
- •Transscleral contact cyclophotocoagulation
- •Complications
- •Excimer laser trabeculotomy
- •References
- •Modulation of wound healing during and after glaucoma surgery
- •The process of wound healing
- •Using surgical and anatomical principles to modify therapy
- •Growth factors
- •Cellular proliferation and vascularization
- •Cell motility, matrix contraction and synthesis
- •Drug delivery
- •Future directions: total scarring control and tissue regeneration
- •Acknowledgments
- •References
- •Surgical alternative to trabeculectomy
- •Introduction
- •Deep sclerectomy
- •Viscocanalostomy
- •Conclusions
- •References
- •Modern aqueous shunt implantation: future challenges
- •Background
- •Current shunts and factors affecting their function
- •Shunt-related factors
- •Surface area
- •Plate material
- •Valved versus non-valved
- •Commercially available devices
- •Comparative studies
- •Patient and ocular factors
- •Severity of glaucoma damage
- •Tolerance of topical ocular hypotensive medications
- •Aqueous hyposecretion
- •Previous ocular surgery
- •Scleral thinning
- •Patient cooperation for and tolerance of potential slit-lamp interventions
- •Future challenges
- •Predictability
- •Cataract formation
- •The long-term effect on the cornea
- •References
- •Model systems for experimental studies: retinal ganglion cells in culture
- •Mixed RGCs in culture
- •Retinal explants
- •Glial cultures
- •RGC-5 cells
- •Differentiation of RGC-5 cells
- •RGC-5 cell neurites
- •Advantages and disadvantages of culture models
- •References
- •Rat models for glaucoma research
- •Rat models for glaucoma research
- •Use of animal models for POAG
- •Suitability of the rat for models of optic nerve damage in POAG
- •Methods for measuring IOP in rats
- •General considerations for measuring IOP in rats
- •Assessing optic nerve and retina damage
- •Experimental methods of producing elevated IOP
- •Laser treatment of limbal tissues
- •Episcleral vein cautery
- •Conclusions
- •Abbreviations
- •Acknowledgements
- •References
- •Mouse genetic models: an ideal system for understanding glaucomatous neurodegeneration and neuroprotection
- •Introduction
- •The mouse as a model system
- •Mice are suitable models for studying IOP elevation in glaucoma
- •Tools for glaucoma research
- •Accurate IOP measurements are fundamental to the study of glaucoma
- •The future of IOP assessment
- •Assessment of RGC function
- •Mouse models of glaucoma
- •Primary open-angle glaucoma
- •MYOC
- •OPTN
- •Strategies for developing new models of POAG
- •Developmental glaucoma
- •Pigmentary glaucoma
- •Experimentally induced models of glaucoma
- •Mouse models to characterize processes involved in glaucomatous neurodegeneration
- •Similar patterns of glaucomatous damage occur in humans and mice
- •The lamina cribrosa is an important site of early glaucomatous damage
- •An insult occurs to the axons of RGCs within the lamina in glaucoma
- •What is the nature of the insult at the lamina?
- •Other changes occur in the retina in glaucoma
- •PERG and complement
- •Using mouse models to develop neuroprotective strategies
- •Somal protection
- •Axonal protection
- •Erythropoietin administration
- •Radiation-based treatment
- •References
- •Clinical trials in neuroprotection
- •Introduction
- •Methods of clinical studies
- •Issues in the design and conduct of clinical trials
- •Clinical trials of neuroprotection
- •Clinical trials of neuroprotection in ophthalmology
- •Endpoints
- •Neuroprotection and glaucoma
- •Conclusions
- •Abbreviations
- •References
- •Pathogenesis of ganglion ‘‘cell death’’ in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria
- •Introduction
- •Retinal ganglion cells and mitochondria
- •Possible causes for ganglion cell death in glaucoma
- •Mitochondrial functions and apoptosis
- •Mitochondrial function enhancement and the attenuation of ganglion cell death
- •Creatine
- •Nicotinamide
- •Epigallocatechin gallate
- •Conclusion
- •References
- •Astrocytes in glaucomatous optic neuropathy
- •Introduction
- •Quiescent astrocytes
- •Reactive astrocytes in glaucoma
- •Signal transduction in glaucomatous astrocytes
- •Protein tyrosine kinases (PTKs)
- •Serine/threonine protein mitogen-activated kinases (MAPKs)
- •G protein-coupled receptors
- •Ras superfamily of small G proteins
- •Astrocyte migration in the glaucomatous optic nerve head
- •Cell adhesion of ONH astrocytes
- •Connective tissue changes in the glaucomatous optic nerve head
- •Extracellular matrix synthesis by ONH astrocytes
- •Extracellular matrix degradation by reactive astrocytes
- •Oxidative stress in ONH astrocytes
- •Conclusions
- •Acknowledgments
- •References
- •Glaucoma as a neuropathy amenable to neuroprotection and immune manipulation
- •Glaucoma as a neurodegenerative disease
- •Oxidative stress and free radicals
- •Excessive glutamate, increased calcium levels, and excitotoxicity
- •Deprivation of neurotrophins and growth factors
- •Abnormal accumulation of proteins
- •Pharmacological neuroprotection for glaucoma
- •Protection of the retinal ganglion cells involves the immune system
- •Searching for an antigen for potential glaucoma therapy
- •Concluding remarks
- •References
- •Oxidative stress and glaucoma: injury in the anterior segment of the eye
- •Introduction
- •Oxidative stress
- •Trabecular meshwork
- •IOP increase and free radicals
- •Glaucomatous cascade
- •Nitric oxide and endothelins
- •Extracellular matrix
- •Metalloproteinases
- •Other factors of interest
- •Therapeutic and preventive substances of interest in glaucoma
- •Ginkgo biloba extract
- •Green tea
- •Ginseng
- •Memantine and its derivates
- •Conclusions
- •Abbreviations
- •References
- •Conclusions on neuroprotective treatment targets in glaucoma
- •Acknowledgments
- •References
- •Involvement of the Bcl2 gene family in the signaling and control of retinal ganglion cell death
- •Introduction
- •Intrinsic apoptosis vs. extrinsic apoptosis
- •The Bcl2 family of proteins
- •The requirement of BAX for RGC soma death
- •BH3-only proteins and the early signaling of ganglion cell apoptosis
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •Assessment of neuroprotection in the retina with DARC
- •Introduction
- •DARC
- •Introducing the DARC technique
- •Annexin 5-labeled apoptosis and ophthalmoloscopy
- •Detection of RGC apoptosis in glaucoma-related animal models with DARC
- •Assessment of glutamate modulation with DARC
- •Glutamate at synaptic endings
- •Glutamate excitotoxicity in glaucoma
- •Assessment of coenzyme Q10 in glaucoma-related models with DARC
- •Summary
- •Abbreviations
- •Acknowledgment
- •References
- •Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection
- •Introduction
- •The endocannabinoid system in the eye
- •The IOP-lowering effects of endocannabinoids
- •Endocannabinoids and neuroprotection
- •Conclusions
- •References
- •Glaucoma of the brain: a disease model for the study of transsynaptic neural degeneration
- •Retinal ganglion cells, retino-geniculate neurons
- •Lateral geniculate nucleus
- •Mechanisms of RGC injury in glaucoma
- •Transsynaptic degeneration of the lateral geniculate nucleus in glaucoma
- •Neural degeneration in magno-, parvo-, and koniocellular LGN layers
- •Visual cortex in glaucoma
- •Neuropathology of glaucoma in the visual pathways in the human brain
- •Mechanisms of glaucoma damage in the central visual pathways
- •Implications of central visual system injury in glaucoma
- •Conclusion
- •Acknowledgments
- •References
- •Clinical relevance of optic neuropathy
- •Is there a remodeling of retinal circuitry?
- •Behavioral consequences of glaucoma
- •Glaucoma as a neurodegenerative disease versus neuroplasticity and adaptive changes
- •Future directions
- •Acknowledgment
- •References
- •Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma
- •Introduction
- •Channel properties of NMDA receptors correlated with excitotoxicity
- •Downstream signaling cascades after overactivation of NMDA receptors
- •Relevance of excitotoxicity to glaucoma
- •Therapeutic approaches to prevent RGC death by targeting the pathways involved in NMDA excitotoxicity
- •Drugs targeting NMDA receptors
- •Kinetics of NMDA receptor antagonists
- •Memantine
- •NitroMemantines
- •Drugs targeting downstream signaling molecules in NMDA-induced cell death pathways
- •p38 MAPK inhibitors
- •Averting caspase-mediated neurodegeneration
- •Abbreviations
- •Acknowledgments
- •References
- •Stem cells for neuroprotection in glaucoma
- •Introduction
- •Glaucoma as a model of neurodegenerative disease
- •Why use stem cells for neuroprotective therapy?
- •Stem cell sources
- •Neuroprotection by transplanted stem cells
- •Endogenous stem cells
- •Key challenges
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •The relationship between neurotrophic factors and CaMKII in the death and survival of retinal ganglion cells
- •Introduction
- •Glaucoma and the RGCs
- •Are other retinal cells affected in glaucoma?
- •Retinal ischemia related glaucoma
- •Excitotoxicity and the retina
- •Signal transduction
- •NMDA receptor antagonists and CaMKII
- •Caspase-3 activation in NMDA-induced retinal cell death and its inhibition by m-AIP
- •BDNF and neuroprotection of RGCs
- •Summary and conclusions
- •Abbreviations
- •Acknowledgments
- •References
- •Evidence of the neuroprotective role of citicoline in glaucoma patients
- •Introduction
- •Patients: selection and recruitment criteria
- •Pharmacological treatment protocol
- •Methodology of visual function evaluation: electrophysiological examinations
- •PERG recordings
- •VEP recordings
- •Statistic evaluation of electrophysiological results
- •Electrophysiological (PERG and VEP) responses in OAG patients after the second period of evaluation
- •Effects of citicoline on retinal function in glaucoma patients: neurophysiological implications
- •Effects of citicoline on neural conduction along the visual pathways in glaucoma patients: neurophysiological implications
- •Possibility of neuroprotective role of citicoline in glaucoma patients
- •Conclusive remarks
- •Abbreviations
- •References
- •Neuroprotection: VEGF, IL-6, and clusterin: the dark side of the moon
- •Neuroprotection: VEGF-A, a shared growth factor
- •VEGF-A isoforms
- •VEGF-A receptors
- •Angiogenesis, mitogenesis, and endothelial survival
- •Neurotrophic and neuroprotective effect
- •Intravitreal VEGF inhibition therapy and neuroretina toxicity
- •Neuroprotection: clusterin, a multifunctional protein
- •Clusterin/ApoJ: a debated physiological role
- •Clusterin and diseases
- •Clusterin and the nervous system
- •Neuroprotection: IL-6, VEGF, clusterin, and glaucoma
- •Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protection
- •Introduction
- •Ischemia model
- •Neuroprotective effect of Coenzyme Q10 against cell loss yielded by transient ischemia in the RGC layer
- •Retinal ischemia and glutamate
- •Coenzyme Q10 minimizes glutamate increase induced by ischemia/reperfusion
- •Summary
- •Acknowledgment
- •References
- •17beta-Estradiol prevents retinal ganglion cell loss induced by acute rise of intraocular pressure in rat
- •Methods
- •Morphometric analysis
- •Microdialysis
- •Drug application
- •Statistical analysis
- •Results
- •17beta-Estradiol pretreatment minimizes RGC loss
- •Discussion
- •Acknowledgment
References
Akimoto, M., Hangai, M., Okazak, K., Kogishi, J., Honda, Y. and Kaneda, Y. (1998) Growth inhibition of cultured human Tenon’s fibroblastic cells by targeting the E2F transcription factor. Exp. Eye Res., 67: 395–401.
Akiyama, H., Kachi, S., Silva, R.L., Umeda, N., Hackett, S.F., McCauley, D., McCauley, T., Zoltoski, A., Epstein, D.M. and Campochiaro, P.A. (2006) Intraocular injection of an aptamer that binds PDGF-B: a potential treatment for proliferative retinopathies. J. Cell. Physiol., 207(2): 407–412.
Andreev, K., Zenkel, M., Kruse, F., Junemann, A. and Schlotzer-Schrehardt, U. (2006) Expression of bone morphogenetic proteins (BMPs), their receptors, and activins in normal and scarred conjunctiva: role of BMP-6 and activin-A in conjunctival scarring? Exp. Eye Res., 83(5): 1162–1170.
Aoki, F., Kurabayashi, M., Hasegawa, Y. and Kojima, I. (2005) Attenuation of bleomycin-induced pulmonary fibrosis by follistatin. Am. J. Respir. Crit. Care Med., 172(6): 713–720.
Asaria, R.H., Kon, C.H., Bunce, C., Charteris, D.G., Wong, D., Khaw, P.T. and Aylward, G.W. (2001) Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmology, 108(7): 1179–1183.
Barton, K., Budenz, D.L., Khaw, P.T. and Tseng, S.C. (2001) Glaucoma filtration surgery using amniotic membrane transplantation. Invest. Ophthalmol. Vis. Sci., 42(8): 1762–1768.
Batterbury, M., Tebbs, C.A., Rhodes, J.M. and Grierson, I. (2002) Agaricus bisporus (edible mushroom lectin) inhibits ocular fibroblast proliferation and collagen lattice contraction. Exp. Eye Res., 74(3): 361–370.
Blake, D.A., Sahiner, N., John, V.T., Clinton, A.D., Galler, K.E., Walsh, M., Arosemena, A., Johnson, P.Y. and Ayyala, R.S. (2006) Inhibition of cell proliferation by mitomycin C incorporated into P(HEMA) hydrogels. J. Glaucoma, 15(4): 291–298.
Broadway, D.C., Grierson, I., Sturmer, J. and Hitchings, R.A. (1996) Reversal of topical antiglaucoma medication effects on the conjunctiva. Arch. Ophthalmol., 114(3): 262–267.
Bruno, C.A., Eisengart, J.A., Radenbaugh, P.A. and Moroi, S.E. (2006) Subconjunctival placement of human amniotic membrane during high risk glaucoma filtration surgery. Ophthalmic Surg. Lasers Imaging, 37(3): 190–197.
Chang, L., Crowston, J.G., Cordeiro, M.F., Akbar, A.N. and Khaw, P.T. (2000) The role of the immune system in conjunctival wound healing after glaucoma surgery. Surv. Ophthalmol., 45(1): 49–68.
Chen, D., Zhao, M. and Mundy, G.R. (2004) Bone morphogenetic proteins. Growth Factors, 22(4): 233–241.
Chen, S.J., Yuan, W., Mori, Y., Levenson, A., Trojanowska, M. and Varga, J. (1999) Stimulation of type I collagen transcription in human skin fibroblasts by TGF-beta: involvement of Smad 3. J. Invest. Dermatol., 112(1): 49–57.
251
Chihara, E., Dong, J., Ochiai, H. and Hamada, S. (2002) Effects of tranilast on filtering blebs: a pilot study. J. Glaucoma, 11(2): 127–133.
Cho, K.S., Yang, L., Lu, B., Feng, M.H., Huang, X., Pekny, M. and Chen, D.F. (2005) Re-establishing the regenerative potential of central nervous system axons in postnatal mice. J. Cell Sci., 118(Pt 5): 863–872.
Cordeiro, M.F., Gay, J.A. and Khaw, P.T. (1999a) Human anti-transforming growth factor-beta2 antibody: a new glaucoma anti-scarring agent. Invest. Ophthalmol. Vis. Sci., 40(10): 2225–2234.
Cordeiro, M.F., Mead, A., Ali, R.R., Alexander, R.A., Murray, S., Chen, C., York-Defalco, C., Dean, N.M., Schultz, G.S. and Khaw, P.T. (2003) Novel antisense oligonucleotides targeting TGF-beta inhibit in vivo scarring and improve surgical outcome. Gene Ther., 10(1): 59–71.
Cordeiro, M.F., Schultz, G.S., Ali, R.R., Bhattacharya, S.S. and Khaw, P.T. (1999b) Molecular therapy in ocular wound healing. Br. J. Ophthalmol., 83(11): 1219–1224.
Dadeya, S., Kamlesh, K.C. and Fatima, S. (2002) Intraoperative daunorubicin versus conjunctival autograft in primary pterygium surgery. Cornea, 21(8): 766–769.
Daniels, J.T., Cambrey, A.D., Occleston, N.L., Garrett, Q., Tarnuzzer, R.W., Schultz, G.S. and Khaw, P.T. (2003) Matrix metalloproteinase inhibition modulates fibroblastmediated matrix contraction and collagen production in vitro. Invest. Ophthalmol. Vis. Sci., 44(3): 1104–1110.
Demir, T., Turgut, B., Akyol, N., Ozercan, I., Ulas, F. and Celiker, U. (2002) Effects of amniotic membrane transplantation and mitomycin C on wound healing in experimental glaucoma surgery. Ophthalmologica, 216(6): 438–442.
Dewald, O., Zymek, P., Winkelmann, K., Koerting, A., Ren, G., bou-Khamis, T., Michael, L.H., Rollins, B.J., Entman, M.L. and Frangogiannis, N.G. (2005) CCL2/Monocyte Chemoattractant Protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ. Res., 96(8): 881–889.
Diestelhorst, M. and Grisanti, S. (2002) Photodynamic therapy to control fibrosis in human glaucomatous eyes after trabeculectomy: a clinical pilot study. Arch. Ophthalmol., 120(2): 130–134.
Drolsum, L., Willoch, C. and Nicolaissen, B. (2006) Use of amniotic membrane as an adjuvant in refractory glaucoma. Acta Ophthalmol. Scand., 84(6): 786–789.
Fujishima, H., Shimazaki, J., Shinozaki, N. and Tsubota, K. (1998) Trabeculectomy with the use of amniotic membrane for uncontrollable glaucoma. Ophthalmic. Surg. Lasers, 29(5): 428–431.
Garrett, Q., Khaw, P.T., Blalock, T.D., Schultz, G.S., Grotendorst, G.R. and Daniels, J.T. (2004) Involvement of CTGF in TGF-beta1-stimulation of myofibroblast differentiation and collagen matrix contraction in the presence of mechanical stress. Invest. Ophthalmol. Vis. Sci., 45(4): 1109–1116.
Gillies, M.C., Brooks, A.M.V., Young, S., Gillies, B., Simpson, J.M. and Goldberg, I. (1999) A randomized phase II trial of interferon-alpha2b versus 5-fluorouracil after trabeculectomy. Aust. N. Z. J. Ophthalmol., 27(1): 37–44.
252
Gomes dos Santos, A.L., Bochot, A., Doyle, A., Tsapis, N., Siepmann, J., Siepmann, F., Schmaler, J., Besnard, M., Behar-Cohen, F. and Fattal, E. (2006) Sustained release of nanosized complexes of polyethylenimine and anti-TGF-beta 2 oligonucleotide improves the outcome of glaucoma surgery. J. Control. Release, 112(3): 369–381.
Gray, A.J., Bishop, J.E., Reeves, J.T. and Laurent, G.J. (1993) A alpha and B beta chains of fibrinogen stimulate proliferation of human fibroblasts. Issue Series Title: J. Cell Sci., 104(Pt 2): 409–413.
Grisanti, S., Diestelhorst, M., Heimann, K. and Krieglstein, G. (1999) Cellular photoablation to control postoperative fibrosis in a rabbit model of filtration surgery. Br. J. Ophthalmol., 83(12): 1353–1359.
Grisanti, S., Gralla, A., Maurer, P., Diestelhorst, M., Krieglstein, G. and Heimann, K. (2000) Cellular photoablation to control postoperative fibrosis in filtration surgery: in vitro studies. Exp. Eye Res., 70(2): 145–152.
Grisanti, S., Szurman, P., Warga, M., Kaczmarek, R., Ziemssen, F., Tatar, O. and Bartz-Schmidt, K.U. (2005) Decorin modulates wound healing in experimental glaucoma filtration surgery: a pilot study. Invest. Ophthalmol. Vis. Sci., 46(1): 191–196.
He, J. and Bazan, H.E. (2006) Synergistic effect of plateletactivating factor and tumor necrosis factor-alpha on corneal myofibroblast apoptosis. Invest. Ophthalmol. Vis. Sci., 47(3): 883–891.
Herrero-Vanrell, R. and Refojo, M.F. (2001) Biodegradable microspheres for vitreoretinal drug delivery. Adv. Drug Deliv. Rev., 52(1): 5–16.
Hill, R.A., Crean, D.H., Doiron, D.R., Ghosheh, F., Ryan, J.A., Kelly, H., Booth, M., Liaw, L.H., Newman, L. and Berns, M.W. (1997) Photodynamic therapy of the ciliary body with tin ethyl etiopurpurin and tin octaethyl benzochlorin in pigmented rabbits. Ophthalmic Surg. Lasers, 28(11): 948–953.
Honjo, M., Tanihara, H., Kameda, T., Kawaji, T., Yoshimura, N. and Araie, M. (2007) Potential role of Rhoassociated protein kinase inhibitor Y-27632 in glaucoma filtration surgery. Invest. Ophthalmol. Vis. Sci., 48(12): 5549–5557.
Hueber, A., Esser, J.M., Kociok, N., Welsandt, G., Luke, C., Roters, S. and Esser, P.J. (2007) Mitomycin C induces multidrug resistance in glaucoma surgery. Graefes Arch. Clin. Exp. Ophthalmol., 246: 297–304.
Jampel, H.D. and Moon, J. (1998) The effect of paclitaxel powder on glaucoma filtration surgery in rabbits. J. Glaucoma, 7: 170–177.
Jampel, H.D., Moon, J.H., Quigley, H.A., Barron, Y. and Lam, K.-W. (1998) Aqueous humor uric acid and ascorbic acid concentrations and outcome of trabeculectomy. Arch. Ophthalmol., 116: 281–285.
Jampel, H.D., Thibault, D., Leong, K.W., Uppal, P. and Quigley, H.A. (1993) Glaucoma filtration surgery in nonhuman primates using taxol and etoposide in polyanhydride carriers. Invest. Ophthalmol. Vis. Sci., 34(11): 3076–3083.
Jordan, J.F., Diestelhorst, M. and Grisanti, S. (2003) Photodynamic modulation of wound healing in glaucoma filtration surgery. Br. J. Ophthalmol., 87: 870–875.
Joseph, J.P., Grierson, I. and Hitchings, R.A. (1989) Taxol, cytochalasin B, and colchicine effects on fibroblast migration and contraction: a role in glaucoma filtration surgery? Cur. Eye Res., 8(2): 203–215.
Kapetansky, F.M., Pappa, K.S., Krasnow, M.A., Baker, N.D. and Francis, C.D. (2008). Subconjunctival injection(s) of Bevacizumab for failing filtering blebs. Invest. Ophthalmol. Vis. Sci. ARVO 49 [E-Abstract 4149].
Kent, A.R., Dubiner, H.B., Whitaker, R., Mundorf, T.K., Stewart, J.A., Cate, E.A. and Stewart, W.C. (1998) The efficacy and safety of diclofenac 0.1% versus prednisolone acetate 1% following trabeculectomy with adjunctive mito- mycin-C. Ophthalmic Surg. Lasers, 29(7): 562–569.
Khaw, P., Grehn, F., Hollo, G., Overton, B., Wilson, R., Vogel, R. and Smith, Z. (2007) A phase III study of subconjunctival human anti-transforming growth factor beta(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. Ophthalmology, 114(10): 1822–1830.
Khaw, P.T., Occleston, N.L., Schultz, G., Grierson, I., Sherwood, M.B. and Larkin, G. (1994) Activation and suppression of fibroblast function. Eye, 8(Pt 2): 188–195.
Khaw, P.T., Ward, S., Grierson, I. and Rice, N.S. (1991) Effect of beta radiation on proliferating human Tenon’s capsule fibroblasts. Br. J. Ophthalmol., 75(10): 580–583.
Kim, E.K., Peterson, T.G. and Barnes, S. (1998) Mechanisms of action of the soy isoflavone genistein: emerging role for its effects via transforming growth factor beta signaling pathways. Am. J. Clin. Nutr., 68(6 Suppl.): S1418–S1425.
Kim, J.H., Jeong, S.Y., Jung, M.H. and Hwang, J.M. (2004) Use of polyurethane with sustained release dexamethasone in delayed adjustable strabismus surgery. Br. J. Ophthalmol., 88(11): 1450–1454.
Kirwan, J.F., Constable, P.H., Murdoch, I.E. and Khaw, P.T. (2003) Beta irradiation: new uses for an old treatment: a review. Eye, 17(2): 207–215.
Kirwan, J.F., Cousens, S., Venter, L., Cook, C., Stulting, A., Roux, P. and Murdoch, I. (2006) Effect of beta radiation on success of glaucoma drainage surgery in South Africa: randomised controlled trial. BMJ, 333(7575): p. 942.
Koz, O.G., Ozhuy, S., Tezel, G.G., Karaman, N., Unlu, N., Yarangumeli, A. and Kural, G. (2007) The effect of paclitaxel on conjunctival wound healing: a pilot study. J. Glaucoma, 16(7): 610–615.
Lattanzio, F.A., Jr., Crouch, E.R., Jr., Mitrev, P.V., Williams, P.B. and Allen, R.C. (2005) Cyclosporin as an adjunct to glaucoma filtration surgery. J. Glaucoma, 14(6): 441–447.
Leask, A. and Abraham, D.J. (2004) TGF-beta signaling and the fibrotic response. FASEB J., 18(7): 816–827.
Li, Y., Li, D., Khaw, P.T. and Raisman, G. (2008) Transplanted olfactory ensheathing cells incorporated into the optic nerve head ensheathe retinal ganglion cell axons: possible relevance to glaucoma. Neurosci. Lett., 440(3): 251–254 [Epub 2008 May 28].
Lobmann, R., Ambrosch, A., Seewald, M., Dietlein, M., Zink, K., Kullmann, K.H. and Lehnert, H. (2004) Antibiotic therapy for diabetic foot infections: comparison of cephalosporines with chinolones. Diabetes Nutr. Metab., 17(3): 156–162.
Lopes, J.F., Moster, M.R., Wilson, R.P., Altangerel, U., Alvim, H.S., Tong, M.G., Fontanarosa, J. and Steinmann, W.C. (2006) Subconjunctival sodium hyaluronate 2.3% in trabeculectomy: a prospective randomized clinical trial. Ophthalmology, 113(5): 756–760.
Massague, J. (1999) Wounding Smad. Nat. Cell Biol., 1(5): E117–E119.
McGuigan, L.J., Mason, R.P., Sanchez, R. and Quigley, H.A. (1987b) D-pencillamine and betaminopropionitrile effects on experimental filtering surgery. Invest. Ophthalmol. Vis. Sci., 28(10): 1625–1629.
Mead, A.L., Wong, T.T.L., Cordiero, M.F., Anderson, I.K. and Khaw, P.T. (2003) Anti-transforming growth factor-b2 antibody: a new post operative anti-scarring agent in glaucoma surgery. Invest. Ophthalmol. Vis. Sci., 44: 3394–3401.
Meyer-ter-Vehn, T., Gebhardt, S., Sebald, W., Buttmann, M., Grehn, F., Schlunck, G. and Knaus, P. (2006) p38 inhibitors prevent TGF-beta-induced myofibroblast transdifferentiation in human tenon fibroblasts. Invest. Ophthalmol. Vis. Sci., 47(4): 1500–1509.
Mietz, H., Chevez-Barrios, P., Feldman, R.M. and Lieberman, M.W. (1998) Suramin inhibits wound healing following filtering procedures for glaucoma. Br. J. Ophthalmol., 82: 816–820.
Mietz, H. and Krieglstein, G.K. (2001) Suramin to enhance glaucoma filtering procedures: a clinical comparison with mitomycin. Ophthalmic Surg. Lasers, 32(5): 358–369.
Nagineni, C.N., Kutty, V., Detrick, B. and Hooks, J.J. (2005) Expression of PDGF and their receptors in human retinal pigment epithelial cells and fibroblasts: regulation by TGFbeta. J. Cell. Physiol., 203(1): 35–43.
Nakamura, H., Siddiqui, S.S., Shen, X., Malik, A.B., Pulido, J.S., Kumar, N.M. and Yue, B.Y. (2004) RNA interference targeting transforming growth factor-beta type II receptor suppresses ocular inflammation and fibrosis. Mol. Vis., 10: 703–711.
Oshima, Y., Sakamoto, T., Nakamura, T., Tahara, Y., Goto, Y., Ishibashi, T. and Inomata, H. (1999) The comparative benefits of glaucoma filtering surgery with an electric-pulse targeted drug delivery system demonstrated in an animal model. 106(6): 1140–1146.
Paikal, D., Zhang, G., Cheng, Q. and Lee, D.A. (2000) The effect of integrin antibodies on the attachment and proliferation of human Tenon’s capsule fibroblasts. Exp. Eye Res., 70(4): 393–400.
Patella, S., Phillips, D.J., Tchongue, J., de Kretser, D.M. and Sievert, W. (2006) Follistatin attenuates early liver fibrosis: effects on hepatic stellate cell activation and hepatocyte apoptosis. Am. J. Physiol. Gastrointest. Liver Physiol., 290(1): G137–G144.
Perkins, T.W., Faha, B., Ni, M., Kiland, J.A., Poulsen, G.L., Antelman, D., Atencio, I., Shinoda, J., Sinha, D., Brumback,
253
L., Maneval, D., Kaufman, P.L. and Nickells, R.W. (2002) Adenovirus-mediated gene therapy using human p21WAF-1/ Cip-1 to prevent wound healing in a rabbit model of glaucoma filtration surgery. Arch. Ophthalmol., 120(7): 941–949.
Priglinger, S.G., Alge, C.S., Kook, D., Thiel, M., Schumann, R., Eibl, K., Yu, A., Neubauer, A.S., Kampik, A. and WelgeLussen, U. (2006) Potential role of tissue transglutaminase in glaucoma filtering surgery. Invest. Ophthalmol. Vis. Sci., 47(9): 3835–3845.
Rabowsky, J.H., Dukes, A.J., Lee, D.A. and Leong, K.W. (1996) The use of bioerodible polymers and daunorubicin in glaucoma filtration surgery. Ophthalmology, 103: 800–807.
Rauscher, F.M., Barton, K., Budenz, D.L., Feuer, W.J. and Tseng, S.C. (2007) Long-term outcomes of amniotic membrane transplantation for repair of leaking glaucoma filtering blebs. Am. J. Ophthalmol., 143(6): 1052–1054.
Reddi, A.H. (1997a) BMPs: actions in flesh and bone. Nat. Med., 3(8): 837–839.
Reddi, A.H. (1997b) Bone morphogenetic proteins: an unconventional approach to isolation of first mammalian morphogens. Cytokine Growth Factor Rev., 8(1): 11–20.
Saika, S. (2006) TGFbeta pathobiology in the eye. Lab. Invest., 86(2): 106–115.
Saika, S., Kono-Saika, S., Tanaka, T., Yamanaka, O., Ohnishi, Y., Sato, M., Muragaki, Y., Ooshima, A., Yoo, J., Flanders, K.C. and Roberts, A.B. (2004) Smad3 is required for
dedifferentiation of retinal |
pigment epithelium |
follow- |
ing retinal detachment in |
mice. Lab. Invest., |
84(10): |
1245–1258. |
|
|
Saika, S., Ooshima, A., Yamanaka, O., Okada, Y., Tanaka, S. and Ohnishi, Y. (1996) Effect of fibrostatin C, an inhibitor of prolyl 4-hydroxylase, on collagen secretion by human Tenon’s capsule fibroblasts in vitro. Graefes Arch. Clin. Exp. Ophthalmol., 234(Suppl. 1): S214–S222.
Saika, S., Yamanaka, O., Ikeda, K., Kim-Mitsuyama, S., Flanders, K.C., Yoo, J., Roberts, A.B., Nishikawa-Ishida, I., Ohnishi, Y., Muragaki, Y. and Ooshima, A. (2005) Inhi-
bition of |
p38MAP |
kinase |
suppresses fibrotic reaction |
of retinal |
pigment |
epithelial |
cells. Lab. Invest., 85(7): |
838–850.
Sakaguchi, H., Takai, S., Sakaguchi, M., Sugiyama, T., Ishihara, T., Yao, Y., Miyazaki, M. and Ikeda, T. (2002b) Chymase and angiotensin converting enzyme activities in a hamster model of glaucoma filtering surgery. Curr. Eye Res., 24(5): 325–331.
Schiller, M., Javelaud, D. and Mauviel, A. (2004) TGF-beta- induced SMAD signaling and gene regulation: consequences for extracellular matrix remodeling and wound healing. J. Dermatol. Sci., 35(2): 83–92.
Shaunak, S., Thomas, S., Gianasi, E., Godwin, A., Jones, E., Teo, I., Mireskandari, K., Luthert, P., Duncan, R., Patterson, S., Khaw, P. and Brocchini, S. (2004) Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nat. Biotechnol., 22(8): 977–984.
Shinohara, K., Tanaka, M., Sakuma, T. and Kobayashi, Y. (2003) Efficacy of daunorubicin encapsulated in liposome for
254
the treatment of proliferative vitreoretinopathy. Ophthalmic Surg. Lasers Imaging, 34(4): 299–305.
Singhal, S., Lawrence, J.M., Bhatia, B., Ellis, J.S., Kwan, A.S., Macneil, A., Luthert, P.J., Fawcett, J.W., Perez, M.T., Khaw, P.T. and Limb, G.A. (2008) Chondroitin sulphate proteoglycans and microglia prevent migration and integration of grafted Muller stem cells into degenerating retina. Stem Cells, 26(4): 1074–1082 [Epub 2008 Jan 24].
Siriwardena, D., Khaw, P.T., King A.J., Donaldson, M.L., Overton, B.M., Migdal, C. and Cordeiro, M.F. (2002). Human antitransforming growth factor beta(2) monoclonal antibody–a new modulator of wound healing in trabeculectomy: a randomized placebo controlled clinical study. 109(3): 427–431.
Stasi, K., Paccione, J., Bianchi, G., Friedman, A. and Danias, J. (2006) Photodynamic treatment in a rabbit model of glaucoma surgery. Acta Ophthalmol. Scand., 84(5): 661–666.
Tham, C.C., Li, F.C., Leung, D.Y., Kwong, Y.Y., Yick, D.W., Chi, C.C. and Lam, D.S. (2006) Intrableb triamcinolone acetonide injection after bleb-forming filtration surgery (trabeculectomy, phacotrabeculectomy, and trabeculectomy revision by needling): a pilot study. Eye, 20(12): 1484–1486.
Tsuchida, K. (2004) Activins, myostatin and related TGF-beta family members as novel therapeutic targets for endocrine, metabolic and immune disorders. Curr. Drug Targets. Immune. Endocr. Metabol. Disord., 4(2): 157–166.
Watts, K.L., Sampson, E.M. and Schultz, G.S. (2005) Simvastatin inhibits growth factor expression and modulates profibrogeneic markers in lung fibroblasts. Am. J. Respir. Cell Mol. Biol., 32: 290–300.
Wells, A.P., Bunce, C. and Khaw, P.T. (2004) Flap and suture manipulation after trabeculectomy with adjustable sutures: Titration of flow intraocular pressure in guarded filtration surgery. J. Glaucoma., 13(5): 400–406.
Wells, A.P., Cordeiro, M.F., Bunce, C. and Khaw, P.T. (2003) Cystic bleb formation and related complications in limbusversus fornix-based conjunctival flaps in pediatric and young adult trabeculectomy with mitomycin C. Ophthalmology, 110(11): 2192–2197.
Wong, T.T., Mead, A.L. and Khaw, P.T. (2003) Matrix metalloproteinase inhibition modulates postoperative scarring after experimental glaucoma filtration surgery. Invest. Ophthalmol. Vis. Sci., 44(3): 1097–1103.
Wong, T.T., Mead, A.L. and Khaw, P.T. (2005) Prolonged antiscarring effects of ilomastat and MMC after experimental glaucoma filtration surgery. Invest. Ophthalmol. Vis. Sci., 46(6): 2018–2022.
Wong, H.T., Seah, S.K. and Tym, W.H. (1999) Augmentation of filtering blebs with perfluoropropane gas bubble: an experimental and pilot clinical study. Ophthalmology, 106(3): 545–549.
Wu, X.Y., Yang, Y.M., Guo, H. and Chang, Y. (2006) The role of connective tissue growth factor, transforming growth factor beta1 and Smad signaling pathway in cornea wound healing. Chin. Med. J. (Engl.), 119(1): 57–62.
WuDunn, D. (1997) Intracameral urokinase for dissolution of fibrin or blood clots after glaucoma surgery. Am. J. Ophthalmol., 124(5): 693–695.
Yamanaka, O., Saika, S., Ohnishi, Y., Kim-Mitsuyama, S., Kamaraju, A.K. and Ikeda, K. (2007) Inhibition of p38MAP kinase suppresses fibrogenic reaction in conjunctiva in mice. Mol. Vis., 13: 1730–1739.
Yasukawa, T., Kimura, H., Tabata, Y. and Ogura, Y. (2001) Biodegradable scleral plugs for vitreoretinal drug delivery. Adv. Drug Deliv. Rev., 52(1): 25–36.
Zimmermann, T.J., Kooner, K.S., Sharir, M. and Fechner, R.D. (1997) Textbook of ocular pharmacology. Lippincott Raven, Philadelphia.